

Globus Pharma signs binding agreement to supply cannabis to a Canadian company

Minimum estimated income of about \$300 million over two years

Ashkelon, June 14 - 2018 Together (TASE: TGDR) has announced that Globus Pharma, its operations company specializing in growing and producing medical cannabis, has signed a binding agreement to supply cannabis produce to a Canadian company, following the company's announcement in April that it had signed a memorandum of understanding with the company.

The Canadian company has a license to grow, produce and import medical cannabis in the country, and as part of the agreement, it has committed to purchase 5-50 tons of dried cannabis inflorescences, or 500 kilograms to 5 tons of cannabis oil in 2019. From January 1, 2020, the Canadian company has committed to purchase from Globus Pharma 20-50 tons of dried inflorescences or 2-5 tons of oil.

The price at which the purchase will be carried out is a minimum of US\$3 per gram of dried inflorescences or a minimum of \$30,000 for 1 kilogram of oil. As these are minimum prices, and if the sale price of the Canadian company's products will be higher than \$10 per gram of dried inflorescences or higher than \$100,000 per 1 kilogram of oil, Globus will receive 30% of the sale price. This rate reflects a higher price than \$3 per gram of dried inflorescences and \$30,000 per kilogram of cannabis oil. In such a case then Together's income will be higher.

Together CEO Nissim Bracha: "We are delighted with the signing of the first binding agreement to supply cannabis produce to the Canadian company, which will yield large-scale income for our company. It is our intention to supply the cannabis from our farm in Israel or Africa, both of which are in the process of being swiftly built, and in the future will already supply the first produce by the first quarter of 2019."

"Due to the demand that we identify in the market and following the receipt of many enquiries, we are checking out the establishment of an additional large farm in a country outside of Israel so that we can push forward with more supply agreements. Looking ahead, we expect to receive approval to export from Israel although the success of our operations is not dependent on it."

"Israeli cannabis produce has a big advantage worldwide at this stage due to the ideal climate and growing conditions in Israel, and due to the major knowhow gained over the years in various agricultural produce in the country and the use of the most advanced technology, factors that translate into low production costs and consequently attractive sales prices. We hope that as

well as creating value for the company's shareholders, we can also play a significant role in developing a major export sector for the State of Israel."

The company was represented in the transaction by Advs. Ilan Gerzi and Nir Zohar of the Pearl Cohen law firm.

About Together and Globus Pharma

Together (TASE: TGTR) specializes in medical cannabis through its subsidiary Globus Pharma – the agro-technology company, which is currently setting up an advanced agricultural and technological infrastructure for growing, producing and marketing medical cannabis in Israel and abroad. The company has marketing and distribution agreements with leading companies in the medical cannabis sector in Germany and Canada amounting to an overall 80 tons of produce annually. Together Pharma has more than 20 years of knowhow in growing medical cannabis that meets the strictest international standards, and it is in advanced stages of receiving marketing approval in Germany and the entire European market, including submitting a request to receive a European permit for exporting medical cannabis products and receiving a license to distribute them throughout Europe.

<https://together-pharma.com>